GuidelineCA: a cancer journal for clinicians2020
Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement.
Guideline in CA: a cancer journal for clinicians, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- Understanding Cardio-Oncology: A Survey-Based Study Conducted by the Heart Failure Association of the Polish Cardiac Society and the Polish Society of Clinical Oncology.Journal of clinical medicine · 2026Article
- Identification and mechanism analysis of biomarkers related to butyrate metabolism in COVID-19 patients.Annals of medicine · 2025Article
- Quality-of-Care Measures for Cardio-Oncology: An IC-OS and ACC Cardio-Oncology Leadership Council Perspective.JACC. CardioOncology · 2025Review
- Mobile/wearable digital devices for care of active cancer patients: a survey from the ESC Council of Cardio-Oncology.European heart journal. Digital health · 2025Article
- Telemedicine in Care of Sarcoma Patients beyond the COVID-19 Pandemic: Challenges and Opportunities.Cancers · 2023Review
- Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology.Current cardiology reports · 2023Review
- Developing a Novel Immune-Related Seven-Gene Signature and Immune Infiltration Pattern in Patients with COVID-19 and Cardiovascular Disease.Journal of cardiovascular development and disease · 2022Article
- Identification of GINS1 as a therapeutic target in the cancer patients infected with COVID-19: a bioinformatics and system biology approach.Hereditas · 2022Article
- Ongoing Clinical Trials in Aging-Related Tissue Fibrosis and New Findings Related to AhR Pathways.Aging and disease · 2022Review
- The Impact of the COVID-19 Pandemic on the Organization of Cardio-Hematology Care-A Polish Single Center Experience.Medicina (Kaunas, Lithuania) · 2022Article
- Cancer service delivery and the impact of the COVID-19 pandemic in sub-Saharan Africa: a scoping review.Ecancermedicalscience · 2022Article
- Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story.Frontiers in cardiovascular medicine · 2022Article
- Clinical characteristics, risk factors, and cardiac manifestations of cancer patients with COVID-19.Journal of applied physiology (Bethesda, Md. : 1985) · 2021Article
- Impact of cancer and cardiovascular disease on in-hospital outcomes of COVID-19 patients: results from the american heart association COVID-19 cardiovascular disease registry.Cardio-oncology (London, England) · 2021Article
- ANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO).European heart journal supplements : journal of the European Society of Cardiology · 2021Article
- Consumer Wearables and the Integration of New Objective Measures in Oncology: Patient and Provider Perspectives.JMIR mHealth and uHealth · 2021Review
- The Role and Impact of Social Media in Cardio-oncology During the COVID-19 Pandemic.Current oncology reports · 2021Review
- Impact of Cancer and Cardiovascular Disease on In-Hospital Outcomes of COVID-19 Patients: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry.Research square · 2021Article
- Cardio-oncology Training in the COVID-19 Era.Current treatment options in oncology · 2021Review
- Cardiotoxicity of Immune Checkpoint Inhibitors.Current oncology reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 15 institutions in 4 countries.
Funding
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has given rise to a pandemic of unprecedented proportions in the modern era because of its highly contagious nature and impact on human health and society: coronavirus disease 2019 (COVID-19). Patients with cardiovascular (CV) risk factors and established CV disease (CVD) are among those initially identified at the highest risk for serious complications, including death. Subsequent studies have pointed out that patients with cancer are also at high risk for a critical disease course. Therefore, the most vulnerable patients are seemingly those with both cancer and CVD, and a careful, unified approach in the evaluation and management of this patient population is especially needed in times of the COVID-19 pandemic. This review provides an overview of the unique implications of the viral outbreak for the field of cardio-oncology and outlines key modifications in the approach to this ever-increasing patient population. These modifications include a shift toward greater utilization of cardiac biomarkers and a more focused CV imaging approach in the broader context of modifications to typical practice pathways. The goal of this strategic adjustment is to minimize the risk of SARS-CoV-2 infection (or other future viral outbreaks) while not becoming negligent of CVD and its important impact on the overall outcomes of patients who are being treated for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.